pascolizumab
mAbexperimental
Pascolizumab is a humanized monoclonal antibody for the treatment of asthma. A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma was conducted in 2001/2002. Development was discontinued as it showed little benefit. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2001 (NCT00024544)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-4INHIBITOR
IL4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPascolizumab ↗
- ChEMBLCHEMBL2108119 ↗
Also known as
- pascolizumab
- pascolizumab
- sb-240683
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01638520 | Phase 2 | Jun 1, 2012 | National University of Singapore |
| NCT00024544 | Phase 2 | Aug 1, 2001 | Facet Biotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Facet Biotech | For profit | 1 | 1 | 1 | 2001 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2012 |
2 organizations
Page 1 / 1